Pathophysiology of myocardial ischaemia and the prevention of necrosis.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D003329:Coronary Vasospasm / Q000188:drug therapy / Q000503:physiopathology; D003971:Diastole; D006801:Humans; D008833:Microcirculation / Q000187:drug effects; D009203:Myocardial Infarction / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009336:Necrosis; D005996:Nitroglycerin / Q000627:therapeutic use; D010101:Oxygen Consumption / Q000187:drug effects; D010974:Platelet Aggregation; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D005996:Nitroglycerin